dantrolene has been researched along with Cardiac Failure in 21 studies
Dantrolene: Skeletal muscle relaxant that acts by interfering with excitation-contraction coupling in the muscle fiber. It is used in spasticity and other neuromuscular abnormalities. Although the mechanism of action is probably not central, dantrolene is usually grouped with the central muscle relaxants.
dantrolene : The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin. A ryanodine receptor antagonist used for the relief of chronic severe spasticity and malignant hyperthermia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results of this trial will clarify the efficacy and safety of dantrolene for ventricular arrhythmia, as well as mortality and morbidity in patients with chronic heart failure and reduced ejection fraction during guideline-directed medical treatment." | 9.34 | A multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of dantrolene on ventricular arrhythmia as well as mortality and morbidity in patients with chronic heart failure (SHO-IN trial): rationale and design. ( Akashi, S; Furutani, Y; Harada, M; Hiromoto, M; Hisamatsu, Y; Ikeda, Y; Kawamura, S; Kobayashi, S; Kohno, M; Michishige, H; Nakamura, Y; Obayashi, M; Oda, T; Omura, M; Ono, S; Satoh, A; Seki, K; Uchida, K; Wakeyama, T; Yano, M, 2020) |
| "Ryanodine receptor 2 (RyR2) hyperactivity is observed in structural heart diseases that are a result of ischemia or heart failure." | 8.31 | Ryanodine receptor inhibition with acute dantrolene treatment reduces arrhythmia susceptibility in human hearts. ( Brennan-McLean, JA; Efimov, IR; Faye, NR; George, SA; Knollmann, BC; Rytkin, E; Trampel, KA, 2023) |
| "Dantrolene was reported to suppress ventricular fibrillation (VF) in failing hearts with acute myocardial infarction, but its antiarrhythmic efficacy in regional ischemia-reperfusion (IR) hearts remains debatable." | 7.81 | Effects of dantrolene on arrhythmogenicity in isolated regional ischemia-reperfusion rabbit hearts with or without pacing-induced heart failure. ( Chang, PC; Chou, CC; Lee, HL; Wen, MS; Wo, HT; Yeh, SJ, 2015) |
| "Dantrolene prevents arrhythmogenic Ca(2+) release during heart failure (HF)." | 7.80 | Dantrolene suppresses ventricular ectopy and arrhythmogenicity with acute myocardial infarction in a langendorff-perfused pacing-induced heart failure rabbit model. ( Chang, PC; Chou, CC; Lee, HL; Wen, MS; Wo, HT; Wu, D; Yeh, SJ, 2014) |
| "A case is reported of cardiac failure with repeated pulmonary oedema in a female patient suffering from renal failure and having been given incremental doses of dantrolene sodium." | 7.67 | [Cardiac failure caused by an overdose of dantrolene]. ( Bopp, P; Dupeyron, JP; Robillart, A; Vailly, B, 1986) |
| "The results of this trial will clarify the efficacy and safety of dantrolene for ventricular arrhythmia, as well as mortality and morbidity in patients with chronic heart failure and reduced ejection fraction during guideline-directed medical treatment." | 5.34 | A multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of dantrolene on ventricular arrhythmia as well as mortality and morbidity in patients with chronic heart failure (SHO-IN trial): rationale and design. ( Akashi, S; Furutani, Y; Harada, M; Hiromoto, M; Hisamatsu, Y; Ikeda, Y; Kawamura, S; Kobayashi, S; Kohno, M; Michishige, H; Nakamura, Y; Obayashi, M; Oda, T; Omura, M; Ono, S; Satoh, A; Seki, K; Uchida, K; Wakeyama, T; Yano, M, 2020) |
| "Ryanodine receptor 2 (RyR2) hyperactivity is observed in structural heart diseases that are a result of ischemia or heart failure." | 4.31 | Ryanodine receptor inhibition with acute dantrolene treatment reduces arrhythmia susceptibility in human hearts. ( Brennan-McLean, JA; Efimov, IR; Faye, NR; George, SA; Knollmann, BC; Rytkin, E; Trampel, KA, 2023) |
| "The purpose of this study was to investigate the effects of dantrolene on arrhythmogenic triggers and contractile function in human atrial fibrillation (AF) and HF cardiomyocytes (CM)." | 3.85 | Antiarrhythmic effects of dantrolene in human diseased cardiomyocytes. ( Danner, BC; Fischer, TH; Frey, N; Gummert, J; Hartmann, N; Hasenfuss, G; Herting, J; Maier, LS; Pabel, S; Renner, A; Schatter, F; Schotola, H; Sossalla, S, 2017) |
| "Dantrolene was reported to suppress ventricular fibrillation (VF) in failing hearts with acute myocardial infarction, but its antiarrhythmic efficacy in regional ischemia-reperfusion (IR) hearts remains debatable." | 3.81 | Effects of dantrolene on arrhythmogenicity in isolated regional ischemia-reperfusion rabbit hearts with or without pacing-induced heart failure. ( Chang, PC; Chou, CC; Lee, HL; Wen, MS; Wo, HT; Yeh, SJ, 2015) |
| "Dantrolene prevents arrhythmogenic Ca(2+) release during heart failure (HF)." | 3.80 | Dantrolene suppresses ventricular ectopy and arrhythmogenicity with acute myocardial infarction in a langendorff-perfused pacing-induced heart failure rabbit model. ( Chang, PC; Chou, CC; Lee, HL; Wen, MS; Wo, HT; Wu, D; Yeh, SJ, 2014) |
| "A case is reported of cardiac failure with repeated pulmonary oedema in a female patient suffering from renal failure and having been given incremental doses of dantrolene sodium." | 3.67 | [Cardiac failure caused by an overdose of dantrolene]. ( Bopp, P; Dupeyron, JP; Robillart, A; Vailly, B, 1986) |
| "Phenytoin is a hydantoin derivative that is used clinically for the treatment of epilepsy and has been reported to have antiarrhythmic actions on the heart." | 1.56 | Phenytoin Reduces Activity of Cardiac Ryanodine Receptor 2; A Potential Mechanism for Its Cardioprotective Action. ( Ashna, A; Dos Remedios, C; Laver, DR; Molenaar, P; van Helden, DF, 2020) |
| "Dantrolene sodium is a clinically used drug that modulates myocardial [Ca2+]i handling in animal models." | 1.30 | Dantrolene sodium improves the force-frequency relationship and beta-adregenic responsiveness in failing human myocardium. ( Haake, N; Hirt, S; Meissner, A; Min, JY; Simon, R, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 2 (9.52) | 29.6817 |
| 2010's | 9 (42.86) | 24.3611 |
| 2020's | 8 (38.10) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, S | 2 |
| Kobayashi, S | 7 |
| Chang, Y | 1 |
| Nawata, J | 1 |
| Yoshitomi, R | 1 |
| Tanaka, S | 1 |
| Kohno, M | 3 |
| Nakamura, Y | 3 |
| Ishiguchi, H | 1 |
| Suetomi, T | 3 |
| Uchinoumi, H | 5 |
| Oda, T | 5 |
| Okuda, S | 4 |
| Okamura, T | 1 |
| Yamamoto, T | 5 |
| Yano, M | 7 |
| George, SA | 1 |
| Brennan-McLean, JA | 1 |
| Trampel, KA | 1 |
| Rytkin, E | 1 |
| Faye, NR | 1 |
| Knollmann, BC | 1 |
| Efimov, IR | 1 |
| Kajii, T | 1 |
| Shiba, S | 1 |
| Tamitani, M | 1 |
| Nanno, T | 1 |
| Kato, T | 1 |
| Wakeyama, T | 1 |
| Ono, S | 1 |
| Ikeda, Y | 1 |
| Omura, M | 1 |
| Hisamatsu, Y | 1 |
| Seki, K | 1 |
| Satoh, A | 1 |
| Hiromoto, M | 1 |
| Akashi, S | 1 |
| Uchida, K | 1 |
| Harada, M | 1 |
| Furutani, Y | 1 |
| Kawamura, S | 1 |
| Obayashi, M | 1 |
| Michishige, H | 1 |
| Ashna, A | 1 |
| van Helden, DF | 1 |
| Dos Remedios, C | 1 |
| Molenaar, P | 1 |
| Laver, DR | 2 |
| Yoshiga, Y | 1 |
| Spartalis, M | 1 |
| Iliopoulos, DC | 1 |
| Spartalis, E | 1 |
| Athanasiou, A | 1 |
| Paschou, SA | 1 |
| Voudris, V | 1 |
| Siasos, G | 1 |
| Delfiner, MS | 1 |
| Nofi, C | 1 |
| Li, Y | 1 |
| Gerdes, AM | 1 |
| Zhang, Y | 1 |
| Chou, CC | 2 |
| Wen, MS | 2 |
| Lee, HL | 2 |
| Chang, PC | 2 |
| Wo, HT | 2 |
| Yeh, SJ | 2 |
| Wu, D | 1 |
| Seidel, M | 1 |
| Thomas, NL | 1 |
| Williams, AJ | 1 |
| Lai, FA | 1 |
| Zissimopoulos, S | 1 |
| Yang, Y | 1 |
| Li, N | 1 |
| Alsina, KM | 1 |
| Puglisi, JL | 1 |
| Chen-Izu, Y | 1 |
| Cornea, RL | 1 |
| Wehrens, XHT | 1 |
| Bers, DM | 1 |
| Walweel, K | 1 |
| Oo, YW | 1 |
| Hartmann, N | 1 |
| Pabel, S | 1 |
| Herting, J | 1 |
| Schatter, F | 1 |
| Renner, A | 1 |
| Gummert, J | 1 |
| Schotola, H | 1 |
| Danner, BC | 1 |
| Maier, LS | 1 |
| Frey, N | 1 |
| Hasenfuss, G | 1 |
| Fischer, TH | 1 |
| Sossalla, S | 1 |
| Ono, M | 2 |
| Tateishi, H | 2 |
| Mochizuki, M | 1 |
| Xu, X | 2 |
| Koseki, N | 2 |
| Kyushiki, H | 2 |
| Ikemoto, N | 2 |
| Matsuzaki, M | 2 |
| Shannon, TR | 1 |
| Lew, WY | 1 |
| Hino, A | 1 |
| Susa, T | 1 |
| Doi, M | 1 |
| Maxwell, JT | 1 |
| Domeier, TL | 1 |
| Blatter, LA | 1 |
| Meissner, A | 1 |
| Min, JY | 1 |
| Haake, N | 1 |
| Hirt, S | 1 |
| Simon, R | 1 |
| Robillart, A | 1 |
| Bopp, P | 1 |
| Vailly, B | 1 |
| Dupeyron, JP | 1 |
1 review available for dantrolene and Cardiac Failure
| Article | Year |
|---|---|
The emerging role of calmodulin regulation of RyR2 in controlling heart rhythm, the progression of heart failure and the antiarrhythmic action of dantrolene.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calmodulin; Dantrolene; Disease Progression; | 2017 |
1 trial available for dantrolene and Cardiac Failure
| Article | Year |
|---|---|
A multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of dantrolene on ventricular arrhythmia as well as mortality and morbidity in patients with chronic heart failure (SHO-IN trial): rationale and design.
Topics: Chronic Disease; Dantrolene; Double-Blind Method; Female; Heart Failure; Humans; Male; Morbidity; Re | 2020 |
19 other studies available for dantrolene and Cardiac Failure
| Article | Year |
|---|---|
RyR2-targeting therapy prevents left ventricular remodeling and ventricular tachycardia in post-infarction heart failure.
Topics: Animals; Arrhythmias, Cardiac; Calmodulin; Dantrolene; Heart Failure; Mice; Myocardial Infarction; M | 2023 |
RyR2-stabilization therapy with dantrolene against left ventricular remodeling and lethal arrhythmia in heart failure.
Topics: Arrhythmias, Cardiac; Calcium; Dantrolene; Heart Failure; Humans; Ryanodine Receptor Calcium Release | 2023 |
Ryanodine receptor inhibition with acute dantrolene treatment reduces arrhythmia susceptibility in human hearts.
Topics: Action Potentials; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Caffeine; Calcium; Dantrolene; Hear | 2023 |
Dantrolene prevents ventricular tachycardia by stabilizing the ryanodine receptor in pressure- overload induced failing hearts.
Topics: Animals; Dantrolene; Heart Failure; Mice; Muscle Relaxants, Central; Pressure; Protective Agents; Ry | 2020 |
Phenytoin Reduces Activity of Cardiac Ryanodine Receptor 2; A Potential Mechanism for Its Cardioprotective Action.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Calcium; Calcium Channel Blockers; Cardiotonic Age | 2020 |
Author's reply: The RyR2 - Targeting therapy against lethal arrhythmia.
Topics: Arrhythmias, Cardiac; Dantrolene; Double-Blind Method; Heart Failure; Humans; Morbidity; Ryanodine R | 2020 |
The genesis of ventricular arrhythmias in heart failure patients is based on alterations in cardiac mechanical, morphological, metabolic, electrophysiological properties, and neurohumoral remodeling.
Topics: Arrhythmias, Cardiac; Dantrolene; Double-Blind Method; Heart Failure; Humans; Morbidity | 2020 |
Failing Hearts Are More Vulnerable to Sympathetic, but Not Vagal Stimulation-Induced, Atrial Fibrillation-Ameliorated with Dantrolene Treatment.
Topics: Animals; Atrial Fibrillation; Dantrolene; Disease Models, Animal; Electric Stimulation Therapy; Hear | 2018 |
Dantrolene suppresses ventricular ectopy and arrhythmogenicity with acute myocardial infarction in a langendorff-perfused pacing-induced heart failure rabbit model.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Cardiac Pacing, Artificial; Coronary | 2014 |
Dantrolene rescues aberrant N-terminus intersubunit interactions in mutant pro-arrhythmic cardiac ryanodine receptors.
Topics: Amino Acid Substitution; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Arrhythmogenic Right Ventricu | 2015 |
Effects of dantrolene on arrhythmogenicity in isolated regional ischemia-reperfusion rabbit hearts with or without pacing-induced heart failure.
Topics: Animals; Anti-Arrhythmia Agents; Dantrolene; Heart; Heart Failure; Heart Ventricles; Myocardial Infa | 2015 |
CaMKII-dependent phosphorylation of RyR2 promotes targetable pathological RyR2 conformational shift.
Topics: Animals; Calcium; Calcium Signaling; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calmodulin; | 2016 |
Antiarrhythmic effects of dantrolene in human diseased cardiomyocytes.
Topics: Action Potentials; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Signaling; Cells, Cultured; | 2017 |
Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor.
Topics: Animals; Calcium; Dantrolene; Disease Models, Animal; Dogs; Heart Failure; Malignant Hyperthermia; M | 2009 |
Diastolic release of calcium from the sarcoplasmic reticulum: a potential target for treating triggered arrhythmias and heart failure.
Topics: Animals; Arrhythmias, Cardiac; Calcium; Dantrolene; Diastole; Heart Failure; Humans; Membrane Potent | 2009 |
Dissociation of calmodulin from cardiac ryanodine receptor causes aberrant Ca(2+) release in heart failure.
Topics: Animals; Calcium Signaling; Calmodulin; Cardiac Pacing, Artificial; Dantrolene; Disease Models, Anim | 2010 |
Dantrolene prevents arrhythmogenic Ca2+ release in heart failure.
Topics: Animals; Arrhythmias, Cardiac; Calcium; Cells, Cultured; Dantrolene; Disease Models, Animal; Heart F | 2012 |
Dantrolene sodium improves the force-frequency relationship and beta-adregenic responsiveness in failing human myocardium.
Topics: Adrenergic beta-Agonists; Calcium; Calcium Channel Blockers; Dantrolene; Female; Heart Failure; Hear | 1999 |
[Cardiac failure caused by an overdose of dantrolene].
Topics: Acute Kidney Injury; Dantrolene; Female; Heart; Heart Failure; Humans; Middle Aged; Pulmonary Edema | 1986 |